The beneficial effect of a β-D-xyloside, Iliparcil, in the prevention of postthrombolytic rethrombosis in the rat

Haemostasis

Volumn 28, Issue 6, 1998, Pages 313-320

  Chicaud, P ^a   Rademakers, J R ^a   Millet, J ^a  

^a Laboratoires Fournier   (France)

Author keywords

Dermatan sulfate; Iliparcil; Rethrombosis model

Indexed keywords

ANTICOAGULANT AGENT; BETA XYLOSIDE; DERMATAN SULFATE; HEPARIN; ILIPARCIL; UNCLASSIFIED DRUG; UROKINASE;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FIBRINOLYTIC THERAPY; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; THROMBOSIS;

EID: 0032323814     PISSN: 03010147     EISSN: None     Source Type: Journal    
DOI: 10.1159/000022448     Document Type: Article

References (23)

1. TIMI Study Group: The Thrombolysis in Acute Myocardial Infarction (TIMI) trial: Phase I finding. N EngI J Med 1985;312:932-936.
2. Brouwer MA, Bohnecke JR, Veen G, Meijer A, Van Eenige MJ, Verheught FWA: Adverse long-term effect of reocclusion after coronary thrombolysis. J Am Coll Cardiol 1995;26:1440-1444.
3. ISIS-2 (Second International Study of Infarct Survival) Study Group: Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected myocardial infarction: ISIS-2. Lancet 1988;ii:349-360.
4. Parise P, Hauert J, Iorio A, Callegari P, Agnelli G: Streptokinase and rtPA activate platelets by a different way: Implications, on the rethrombosis rate after their administration in myocardial infarction. J Lab Clin Med 1994;125:212-221.
5. Nicolini FA, Nichols WW, Saldeen TCP, Khan S, Metha JL: Adjunctive therapy with low molecular weight heparin with recombinant tissue-type plasminogen activator causes sustained reflow in canine coronary thrombosis. Am Heart J 1992;124:280-288.
6. Yasuda T, Gold HK, Yaoita H, Leinbach RC, Guerrero JL, Jang IK, Holt R, Fallon JT, Collen D: Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation. J Am Coll Cardiol 1990;16:714-722.
7. Umetsu T, Sanai K: Effect of 1-methyl-2 mercapto-5-(3-pyridyl)imidazole (kc-6141), an anti-aggregating compound, on experimental thrombosis in rats. Thromb Haemost 1978;39:74-83.
8. Bellamy F, Barberousse V, Martin N, Masson P, Millet J, Samreth S, Sepulchre C, Theveniaux J, Horton D: Thioxyloside derivatives orally active venous antithrombotics. Eur J Med Chem 1995(suppl 30):102-115.
9. Fareed J, Hoppensteadt D, Walenga JM, Ahsan A, Coyne E, Breddin HK: Molecular and functional heterogeneity in dermatan sulfate preparations. Semin Thromb Hemost 1991; 17:174-180.
10. Vaerstraete M, Lijnen HR, Collen D: Thrombolytic agents in development. Drugs 1995;50:29-42.
11. Okada Y, Yamaguchi T, Minematsu K, Miyashita T, Sawada T, Sadoshima S, Fujishima M, Omae T: Hemorrhagic transformation in cerebral embolism. Stroke 1989;20:598-603.
12. Chen L, Nichols WW, Mattsson C, Teger-Nilsson AC, Saldeen TO, Mehta JL: Inogatran, a novel direct low molecular weight thrombin inhibitor, given with, but not after, tissue-plasminogen activator, improves thrombolysis. J Pharmacol Exp Ther 1996;277:1276-1283.
13. Hinjy S, Shinya S, Hiroshi S, Atsuo N: Fibrinolytic and anticoagulant, activities of highly sulfated fucoidan. Biochem Pharmacol 1992;43:1853-1858.
14. Kelton JG: Heparin-induced thrombocytopenia. Haemostasis 1986;16:173-186.
15. Borris LC, Lassen MR: A comparative review of the adverse effect profiles of heparins and heparinoids. Drug Saf 1995;12:26-31.
16. Leadley RJ Jr, Kasiewski CJ, Bostwick JS, Bentley R, McVey MJ, White FJ, Perrone MH, Dunwiddie CT: Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the Stenosed canine coronary artery. Thromb Haemost 1997;78:1278-1285.
17. Rubsamen K, Hornberger W. Prevention of early reocclusion after thrombolysis of copper coil-induced thrombi in the canine carotid artery: Comparison of PEG-hirudin and unfractionated heparin. Thromb Haemost 1996;76:105-110.
18. Klement D, Rammos S, v Kries R, Kirschke W, Kniemeyer HW, Greinacher A: Heparin as a cause of thrombus progression. Heparin-associated thrombocytopenia is an important differential diagnosis in paediatric patients even with normal platelet counts. Eur J Pediatr 1996;155:11-14.
19. Millet J, Theveniaux J, Vaillot M, Chicaud P, Brown NL: Venous antithrombotic profile of LF05-0030 following oral administration to ras (abstract). Thromb Haemost 1993;69:672.
20. Martin NB, Massen P, Sepulchre C, Theveniaux J, Millet J, Bellamy F: Pharmacologic and biological profiles of venous antithrombotic β-D-xyloside derivatives: Potential antiathero/thrombotic drugs. Semin Thromb Hemost 1996:22:247-254.
21. Tripodi A, Moia M, Bottasso B, Tenconi PM, Gianese F, Mannucci PM: Effects of subcutaneously administered dermatan sulfate (MF 701) on the coagulation and fibrinolytic parameters of healthy volunteers. Thromb Res 1991;62:663-672.
22. Agnelli G, Cosmi B, Di Filippo P, Ranucci V, Veschi F, Longetti M, Renga C, Barzi F, Gianese F, Lupattelli L: A randomised, double-blind, placebo-controlled trial of dermatan sulphate for prevention of deep vein thrombosis in hip fracture. Thromb Haemost 1992; 67:203-208.
23. Masson PJ, Coup D, Millet J, Brown NL: The effect of the β-D-xyloside naroparcil on circulating plasma glycosaminoglycans. An explanation for its known antithrombotic activity in the rabbits. J Biol Chem 1995;270:2662-2668.